• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • ZanthoSyn®
    • CDX-101
    • CDX-301
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI

Press Releases

Investor Relations
Investors
  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Cardax Attracts $2.75M in Investment

Aug 28, 2017

Cardax Reports Q2 2017 Results

Aug 11, 2017

ZanthoSyn Going National with GNC

Aug 10, 2017

ZanthoSyn Now Available on GNC.com

Jun 27, 2017

Cardax Astaxanthin Compound Chosen for Important NIH Anti-Aging Research Program

Jun 18, 2017

Cardax Q1 2017 Revenues Triple vs. Prior Two Quarters Combined

May 15, 2017

Cardax Astaxanthin Compound CDX-085 Stimulates Anti-Aging Gene in Mice

Mar 28, 2017

Cardax Secures Access to Funds Under Equity Purchase Agreement

Feb 9, 2017

Cardax Takes Important Step to Access Funds Under Equity Purchase Agreement

Feb 8, 2017

Cardax Announces Launch of ZanthoSyn™ in Hawaii GNC Stores

Jan 25, 2017
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8

    News / Events

    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
    Subscribe to Receive Updates by E-Mail Cardax News Alerts

    Recent News

    • Cardax Refocuses on ZanthoSyn® Consumer Health BusinessAugust 31, 2021
    • Cardax Voluntarily Suspends SEC Reporting ObligationsAugust 11, 2021
    • Cardax Reports Q1 2021 ResultsMay 14, 2021

    *These statements have not been evaluated by the Food and Drug Administration.
    This product is not intended to diagnose, treat, cure, or prevent any disease.

    © 2023 Cardax, Inc. | Disclaimer and Terms of Use | Accessibility Statement

    • About Us
      • Corporate Overview
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Company History
    • Astaxanthin
      • Overview
        • Astaxanthin Overview
        • History and Background
        • Safety
        • Mechanism of Action
        • Synthetic vs. Natural Astaxanthin
      • Research in Key Addressable Markets
      • Scientific Literature
    • Programs
      • Product Platform
      • Commercialization Strategy
      • ZanthoSyn®
      • CDX-101
      • CDX-301
      • CHASE Clinical Trial
      • Intellectual Property
    • Newsroom
    • Investors
      • Investor Overview
      • News / Events
      • Company Information
      • Financial Information
      • Stock Information
      • SEC Filings
      • Corporate Governance
    • Contact Us
    • Investors
    • News
    • Subscribe